Finally, in HER2+ breast cancer, enzalutamide inhibited growth in trastuzumab-resistant HER2+ breast cancer xenografts [36], which may be attributed to the cross-talk between AR signaling and HER2 signaling [34]. This evidence concerns the gene AR and breast carcinoma.